-

Profluent Named 2026 Emerging Innovator Of The Year At 23rd Annual Pantheon Awards

EMERYVILLE, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Profluent today announced that it has been named the winner of the Emerging Innovator of the Year Award by California Life Sciences (CLS).

The award recognizes a company founded within the last seven years that is advancing novel science, achieving meaningful milestones, and building toward a future that medicine has not yet fully imagined. Profluent was named this year’s award winner for its potentially field-changing AI design platform and highly original approach to AI in life sciences. A team of independent judges identified Profluent’s technology as the strongest of this year’s Emerging Innovator finalists, attributing its strength to substantial experimental validation, publications in industry-leading academic journals, and credible pathways to development through high-profile industry partnerships. The award was presented at the 23rd Annual Pantheon Awards ceremony on November 12, 2026, in San Francisco, where Profluent was recognized alongside fellow innovators, companies, and institutions whose discoveries, technologies, and leadership continue to advance the life sciences industry and improve lives around the world.

About the Pantheon Awards: For over two decades, California Life Sciences (CLS) has recognized the state’s leaders from across the pharmaceutical, biotech and other allied industries to pay tribute to those making exceptional contributions to the life sciences industry. The Pantheon awards recognize excellence and celebrate the contributions and achievements of leading life sciences innovators representing therapeutic, diagnostic, medical device, and industrial biotechnology companies.

About Profluent: Profluent is the frontier AI lab for biology. Profluent builds powerful foundation models for all of life's molecules, unlocking solutions that transform medicine, agriculture, and beyond. Founded in 2022 and headquartered in Emeryville, CA, Profluent is backed by leading investors including Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more, visit www.profluent.bio or follow the company on LinkedIn, X, and YouTube.

About California Life Sciences: California Life Sciences (CLS) is the state’s leading advocate for the life sciences. We represent the entire innovation ecosystem, from startups and global companies to research institutions and service providers. We champion smart policy, foster strategic connections, and deliver resources that help life sciences companies grow and thrive. Based in the global epicenter of innovation, we work to ensure that the discoveries made here translate into healthier lives everywhere.

Contacts

For media inquiries, please contact:

Cas Smith
Head of Communications & Brand
Profluent
press@profluent.bio

Katie Kiss
Senior Director, Marketing
California Life Sciences (CLS)
(858) 456-8894
kkiss@califesciences.org

Profluent


Release Versions

Contacts

For media inquiries, please contact:

Cas Smith
Head of Communications & Brand
Profluent
press@profluent.bio

Katie Kiss
Senior Director, Marketing
California Life Sciences (CLS)
(858) 456-8894
kkiss@califesciences.org

More News From Profluent

Profluent Partners With BioMarin to Design Novel Medicines Using AI

EMERYVILLE, Calif.--(BUSINESS WIRE)--Profluent, the frontier AI lab for biology, today announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational AI models to generate novel potential drug candidates, and BioMarin will screen the results with the goal to eventually advance the most promising designs. Developing and optimizing therapeutic enzymes is a complex process...

Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicine

EMERYVILLE, Calif.--(BUSINESS WIRE)--Profluent, the frontier AI company pioneering large-scale foundation models for protein design, today announced a multi-program strategic research collaboration with Eli Lilly and Company (“Lilly”) to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs. The collaboration focuses on enabling large-scale, precise DNA editing capabilities that remain out of reach using conventional gene editing systems. By com...

Profluent Bio Announces Strategic Collaboration with Ensoma to Develop AI-Designed Base Editors for In Vivo Hematopoietic Stem Cell Therapies

EMERYVILLE, Calif.--(BUSINESS WIRE)--Profluent, a leader in frontier AI for protein design, today announced that it has entered into a strategic collaboration with Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies. Under the agreement, the companies will leverage Profluent’s AI-designed deaminases in connection with Ensoma’s gene editing scaffolds and helper-dependent adenovirus (HDAd) delivery systems to design, develop,...
Back to Newsroom